» Articles » PMID: 16464951

Function of Estrogen-related Receptor Alpha in Human Endometrial Cancer

Overview
Specialty Endocrinology
Date 2006 Feb 9
PMID 16464951
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The estrogen-related receptor alpha (ERRalpha) is an orphan member of the nuclear receptor superfamily that is closely related to estrogen receptor alpha (ERalpha). ERRalpha binds an estrogen response element (ERE), directly competes with ERalpha for binding ERE, and represses ERE-dependent transcription in MCF-7 cells, ER-positive breast cancer cells.

Objective: We investigated whether ERRalpha modulate some ER-dependent activities in endometrial cancer.

Method: We investigated protein and mRNA expression of ERRalpha in endometrial cancer using immunohistochemistry and RT-PCR, respectively. After transient transfection using the ERRalpha expression vector (pCI-ERRalpha) or ERRalphaSi, which suppressed the expression of endogenous ERRalpha, Ishikawa cells were assayed for ERE-dependent luciferase activity. Cells stably overexpressing ERRalpha were generated and compared with estrogen-dependent and -independent cell growth.

Result: ERRalpha was detected in human endometrial cancer tissues by immunohistochemistry. An RT-PCR study showed that mRNA of ERRalpha was expressed in four endometrial cancer cell lines (Ishikawa, Hec1a, KLE, and SNGII) and 11 human endometrial tissues. Overexpression of ERRalpha repressed estrogen-induced ERE-dependent transcriptional activity in Ishikawa cells. After transfection with ERRalphaSi1, the expression of endogenous ERRalpha decreased to 0.5-fold, and estrogen-induced ERE luciferase activity increased to 1.5-fold. The cells stably overexpressing ERRalpha grew up more slowly than control cells in the presence of 10 nm estradiol.

Conclusion: ERRalpha is expressed in human endometrial cancer tissues and cell lines and suppresses ERE-dependent transcriptional activity in the presence of estrogen. ERRalpha modulates estrogen-induced activity in estrogen-dependent endometrial cancer.

Citing Articles

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.


Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer.

Schuler-Toprak S, Skrzypczak M, Grundker C, Ortmann O, Treeck O Cancers (Basel). 2023; 15(10).

PMID: 37345182 PMC: 10216512. DOI: 10.3390/cancers15102845.


Estrogen-Related Receptor α (ERRα) and G Protein-Coupled Estrogen Receptor (GPER) Synergistically Indicate Poor Prognosis in Patients with Triple-Negative Breast Cancer.

Ye S, Xu Y, Wang L, Zhou K, He J, Lu J Onco Targets Ther. 2020; 13:8887-8899.

PMID: 33061416 PMC: 7520096. DOI: 10.2147/OTT.S265372.


Optical Control of Small Molecule-Induced Protein Degradation.

Naro Y, Darrah K, Deiters A J Am Chem Soc. 2020; 142(5):2193-2197.

PMID: 31927988 PMC: 7229639. DOI: 10.1021/jacs.9b12718.


Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.

Kokabu T, Mori T, Matsushima H, Yoriki K, Kataoka H, Tarumi Y Cell Oncol (Dordr). 2019; 42(2):223-235.

PMID: 30706380 DOI: 10.1007/s13402-019-00423-5.